Abstract
Visceral leishmaniasis (VL) is a severe form of leishmaniasis - a disease caused by protozoan parasites and transmitted by the bite of certain species of sand fly. In VL, parasites migrate to the vital organs and bone marrow, destroying white and red blood cells. VL has been called the parasitic version of HIV/AIDs (Human immunodeficiency virus infection / acquired immunodeficiency syndrome), as it attacks the immune system. The most common form of the disease is cutaneous leishmaniasis, which causes skin lesions and often leaves the infected individual permanently disfigured. Even though the disease is treatable, current treatments are difficult to administer, too expensive, or toxic for extensive use in developing nations. Furthermore, resistance to treatment is an increasing problem, particularly in India. 90% of people with VL die if the infection is left untreated, and death can come within 2 years, significantly faster than AIDS. The search for new drugs continues, with new chemical and natural compounds. Many potential drug targets have been identified in biochemical and molecular studies, and some have been validated. Attempts to exploit these targets are in progress. This article reviews the epidemiology, clinical features, control Strategies, diagnosis and current treatment about visceral leishmaniasis.
Keywords: AIDS, Protozoan parasites, Visceral leishmaniasis.
Current Drug Delivery
Title:New Insights into the Diagnosis and Chemotheraphy for Visceral Leishmaniasis
Volume: 11 Issue: 2
Author(s): V. Dinesh Kumar, Priya Ranjan Prasad Verma and Sandeep Kumar Singh
Affiliation:
Keywords: AIDS, Protozoan parasites, Visceral leishmaniasis.
Abstract: Visceral leishmaniasis (VL) is a severe form of leishmaniasis - a disease caused by protozoan parasites and transmitted by the bite of certain species of sand fly. In VL, parasites migrate to the vital organs and bone marrow, destroying white and red blood cells. VL has been called the parasitic version of HIV/AIDs (Human immunodeficiency virus infection / acquired immunodeficiency syndrome), as it attacks the immune system. The most common form of the disease is cutaneous leishmaniasis, which causes skin lesions and often leaves the infected individual permanently disfigured. Even though the disease is treatable, current treatments are difficult to administer, too expensive, or toxic for extensive use in developing nations. Furthermore, resistance to treatment is an increasing problem, particularly in India. 90% of people with VL die if the infection is left untreated, and death can come within 2 years, significantly faster than AIDS. The search for new drugs continues, with new chemical and natural compounds. Many potential drug targets have been identified in biochemical and molecular studies, and some have been validated. Attempts to exploit these targets are in progress. This article reviews the epidemiology, clinical features, control Strategies, diagnosis and current treatment about visceral leishmaniasis.
Export Options
About this article
Cite this article as:
Kumar Dinesh V., Verma Ranjan Prasad Priya and Singh Kumar Sandeep, New Insights into the Diagnosis and Chemotheraphy for Visceral Leishmaniasis, Current Drug Delivery 2014; 11 (2) . https://dx.doi.org/10.2174/15672018113106660057
DOI https://dx.doi.org/10.2174/15672018113106660057 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas
Current Genomics Novel Pentapeptide Activators of Mammalian and Mushroom Tyrosinase
Current Topics in Medicinal Chemistry Editorial [Hot Topic: The Chemistry and Biology of Small Molecules Acting on Nucleic Acids (Guest Editors: P.B. Arimondo, T. Garestier, J.-L. Mergny Dedicated to the Memory of Professor Claude Helene)]
Current Medicinal Chemistry - Anti-Cancer Agents DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Azathioprine in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry Biomarkers of Oxidative Stress and Cataract. Novel Drug Delivery Therapeutic Strategies Targeting Telomere Reduction and the Expression of Telomerase Activity in the Lens Epithelial Cells with N-Acetylcarnosine Lubricant Eye Drops: Anti-Cataract which Helps to Prevent and Treat Cataracts in the Eyes of Dogs and other Animals
Current Drug Delivery Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry The Hedgehog Signaling Pathway as a Target for Anticancer Drug Discovery
Current Topics in Medicinal Chemistry Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer
Current Topics in Medicinal Chemistry Salicylanilide Ester Prodrugs as Potential Antimicrobial Agents - a Review
Current Pharmaceutical Design Biological Activity of Carotenoids: Its Implications in Cancer Risk and Prevention
Current Pharmaceutical Biotechnology Epigallocatechin-3-Gallate Prevents Autoimmune-Associated Down- Regulation of p21 in Salivary Gland Cells Through a p53-Independent Pathway
Inflammation & Allergy - Drug Targets (Discontinued) Box-Behnken Design Optimized TPGS Coated Bovine Serum Albumin Nanoparticles Loaded with Anastrozole
Current Drug Delivery Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies
Current Neuropharmacology Editorial (Thematic Issue: Current Treatments for Skin Cancer Part 2)
Current Cancer Therapy Reviews Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Electrotransfer as a Non Viral Method of Gene Delivery
Current Gene Therapy Editorial (Thematic Issue: Chemoresistance in Gynecologic Cancers)
Current Cancer Therapy Reviews